Autoantibodies to early endosome antigen (EEA1) produce a staining pattern resembling cytoplasmic anti-neutrophil cytoplasmic antibodies (C-ANCA)
S. Selak,
R. C. Woodman,
M. J. Fritzler,
S. Selak
Faculty of Medicine, University of Calgary, Calgary, Canada
Search for more papers by this authorR. C. Woodman
Faculty of Medicine, University of Calgary, Calgary, Canada
Search for more papers by this authorM. J. Fritzler
Faculty of Medicine, University of Calgary, Calgary, Canada
Search for more papers by this authorS. Selak,
R. C. Woodman,
M. J. Fritzler,
S. Selak
Faculty of Medicine, University of Calgary, Calgary, Canada
Search for more papers by this authorR. C. Woodman
Faculty of Medicine, University of Calgary, Calgary, Canada
Search for more papers by this authorM. J. Fritzler
Faculty of Medicine, University of Calgary, Calgary, Canada
Search for more papers by this author Marvin J. Fritzler PhD, MD, Faculty of Medicine, University of Calgary, 3330 Hospital Dr NW, Calgary, AB Canada T2N 4N1. E-mail: [email protected]
Abstract
Autoantibodies to EEA1 have been described in patients with neurological diseases, subacute cutaneous lupus and a variety of other conditions, including a patient with Wegener's granulomatosis (WG). EEA1 is a hydrophilic peripheral membrane protein transiently associated with the cytoplasmic face of early endosomes. Antibodies to EEA1 produce a staining pattern that resembles the C-ANCA pattern produced by anti-proteinase 3 (PR3) antibodies in WG sera. Co-localization studies show incomplete overlap of the staining produced by anti-EEA1 with anti-PR3. We showed that 0/40 unselected sera, from a cohort of WG patients and antibodies to PR3, reacted with EEA1. In addition, 1/15 sera that have a C-ANCA staining pattern but do not react with PR3 in an ELISA, immunoprecipitated the recombinant EEA1 protein. We conclude that although antibodies to EEA1 produce a staining pattern that resembles anti-PR3 and C-ANCA, antibodies to EEA1 in WG are rare. However, some C-ANCA+ sera that do not react with PR3 may contain EEA1 autoantibodies.
References
- 1 Tan EM. Autoantibodies and autoimmunity: a three-decade perspective—a tribute to Henry G. Kunkel. Ann NY Acad Sci 1997; 815: 1–14.
- 2 Fritzler MJ. Autoantibodies: diagnostic fingerprints and etiologic perplexities. Clin Invest Med 1997; 20: 50–66.
- 3 Fritzler MJ, Hamel JC, Ochs RL & Chan EKL. Molecular characterization of two human autoantigens: unique cDNAs encoding 95- and 160-kD proteins of a putative family in the Golgi complex. J Exp Med 1993; 178: 49–62.
- 4 Caldwell SH, Leung PS & Spivey JR et al. Antimitochondrial antibodies in kindreds of patients with primary biliary cirrhosis: antimitochondrial antibodies are unique to clinical disease and are absent in asymptomatic family members. Hepatology 1992; 16: 899–905.
- 5
Bonfa E,
Weissbach H,
Brot N &
Elkon KB.
Ribosomal P protein autoantibodies. In:
JB Peter,
Y Shoenfeld, eds.
Autoantibodies.
Elsevier Science BV, 1996: 721–6.
10.1016/B978-044482383-0/50109-6 Google Scholar
- 6 Mu FT, Callaghan JM & Steele-Mortimer HS et al. EEA1, an early endosomal protein. J Biol Chem 1995; 270: 13503–11.
- 7 Waite RL, Sentry JW, Stenmark H & Toh BH. Autoantibodies to a novel early endosome antigen 1. Clin Immunol Immunopathol 1998; 86: 81–87.
- 8 Marsh M & McMahon HT. The structural era of endocytosis. Science 1999; 285: 215–20.
- 9 Holtzman E. Lysosomes. New York: Plenum Press, 1989.
- 10 Rubino M, Miaczynska M, Lippé R & Zerial M. Selective membrane recruitment of EEA1 suggests a role in directional transport of clathrin-coated vesicles to early endosomes. J Biol Chem 2000; 275: 3745–8.
- 11 Guo W, Sacher M, Barrowman J, Ferro-Novick S & Novick P. Protein complexes in transport vesicle targeting. Trends Cell Biol 2000; 10: 251–5.
- 12 Selak S, Scheonroth L, Senecal J-L & Fritzler MJ. Early endosome antigen 1: an autoantigen associated with neurological diseases. J Invest Med 1999; 47: 311–8.
- 13 Hagen C, Ballieux BEPB, Van Es LA, Daha MR & Van Der Woude FJ. Antineutrophil cytoplasmic autoantibodies: a review of the antigens involved, the assays, and the clinical and possible pathogenetic consequences. Blood 1993; 81: 1996–2002.
- 14 Hoffman GS, Wiegert E & Homburger HA. Antineutrophil cytoplasmic antibodies. Arthritis Rheum 1998; 41: 1521–37.
- 15 Wiik A. Antineutrophil cytoplasmic antibodies. In: NR Rose, E Conway de Macario, JD Folds, CL Lane, RM Nakamura, eds. Manual of clinical laboratory immunology. Washington, DC: American Society for Microbiology, 1997: 954–9.
- 16 Gross WL, Csernok E & Schmitt WH. Antineutrophil cytoplasmic autoantibodies: immunobiological aspects. Klin Wochenschr 1991; 69: 558–66.
- 17 Ludemann J, Utecht B & Gross WL. Anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis recognize an elastolytic enzyme. J Exp Med 1990; 171: 357–62.
- 18 Goldschmeding R, Tervaert JWC, Dolman KM, Kr von dem Borne AEG & Kallenberg CGM. ANCA: a class of vasculitis-associated autoantibodies against myeloid granule proteins: clinical and laboratory aspects and possible pathogenetic implications. Adv Exp Med Biol 1991; 297: 129–39.
- 19 Specks U, Wiegert E & Homburger HA. Human mast cells expressing recombinant proteinase 3 (PR3) as substrate for clinical testing for anti-neutro cytoplasmic antibodies (ANCA). Clin Exp Immunol 1997; 109: 286–95.
- 20 Hauschildt S, Schmitt WH, Csernok E, Flescher E, Rautmann A & Grossbach U. ANCA in systemic vasculites, collagen vascular diseases, rheumatic disorders and inflammatory bowel diseases. Adv Exp Med Biol 2000; 336: 245–51.
- 21 Yang JJ, Falk RJ & Jennette JC. Frequency of anti-bactericidal/permeability-increasing protein (BPI) and anti-azurocidin in patients with renal disease. Clin Exp Immunol 1996; 105: 125–31.
- 22 Wiik A. Anti-neutrophil cytoplasmic antibodies in Wegener's granulomatosis. Some clinical and pathogenetic aspects. Sem Clin Immunol 1995; 9: 5–16.
- 23
Lesavre P.
Antineutrophil cytoplasmic antibodies antigen specificity.
Am J Kidney Dis
1983; 18: 159–63.
10.1016/S0272-6386(12)80873-0 Google Scholar
- 24 Leavitt RY, Fauci AS & Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990; 33: 1101–7.
- 25 Fritzler MJ, Pauls JD, Kinsella TD & Bowen TJ. Antinuclear, anticytoplasmic and anti-Sjögren's syndrome antigen-A (SS-A/Ro) antibodies in female blood donors. Clin Immunol Immunopathol 1985; 36: 120–8.
- 26 Fritzler MJ, Etherington J, Sokoluk C, Kinsella TD & Valencia DW. Antibodies from patients with autoimmune disease react with a cytoplasmic antigen in the Golgi apparatus. J Immunol 1984; 132: 2904–8.
- 27 Fritzler MJ. Autoantibody testing: procedures and significance in systemic rheumatic diseases. Meth Achiev Exp Pathol 1986; 12: 224–60.
- 28 Borregaard N, Heiple J, Simons E & Clark R. Subcellular localization of the b-cytochrome component of the human neutrophil microbicidal oxidase: translocation during activation. J Cell Biol 1983; 97: 52–61.
- 29 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680.
- 30 Towbin H & Gordon J. Immunoblotting and dot immunobinding—current status and outlook. J Immunol Methods 1984; 72: 313–40.
- 31 Mulder A, Broekroelofs J, Horst G, Limburg P, Nelis G & Kallenberg CGM. Anti-neutrophil cytoplasmic antibodies (ANCA) in inflammatory bowel disease (IBD); relation to disease pattern and disease activity. Dig Dis Sci 1994; 39: 545–9.
- 32 Parton RG & Dotti CG. Cell biology of neuronal endocytosis. J Neurosci Res 1993; 36: 1–9.
- 33 Mollinedo F, Borregaard N & Boxer L. Novel trends in neutrophil structure, function and development. Immunol Today 1999; 20: 535–7.
- 34 Borregaard N & Cowland J. Granules of the human neutrophilic polymorphonuclear leukocyte. Blood 1997; 89: 3503–21.
- 35 Goldschmeding R, Van Der Schoot CE, Ten Bokkel Huinink D, Hack CE, Van Den Ende ME, Kallenberg CGM & Von Dem Borne AEGK. Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils. J Clin Invest 1989; 84: 1577–87.
- 36 Wieslander J & Wiik A. ANCA antigens; proteinase 3. In: WJ Van Venrooij, RN Maini, eds. Manual of biological markers of disease. Dordecht, The Netherlands: Kluwer Academic Publishers, 1994: 1–9.
- 37 Bini P, Gabay JE, Teitel A, Melchior M, Zhou JL & Elkon KB. Antineutrophil cytoplasmic autoantibodies in Wegener's granulomatosis recognize conformational epitope(s) on proteinase 3. J Immunol 1992; 149: 1409–15.
- 38 Patki V, Virbasius J, Lane WS, Toh B-H, Shpetner HS & Corvera S. Identification of an early endosomal protein regulated by phosphatidylinositol 3-kinase. Proc Natl Acad Sci USA 1997; 94: 7326–30.
- 39 Vita F, Soranzo MR, Borelli V, Bertoncin P & Zabucchi G. Subcellular localization of the small GTPase Rab 5a in resting and stimulated neutrophils. Exp Cell Res 1996; 227: 367–73.
- 40 Simonsen A, Lippé R & Christoforidis S et al. EEA1 links PI(3)K function to Rab5 regulation of endosome fusion. Nature 1998; 394: 494–8.
- 41 Lawe DC, Patki V, Heller-Harrison R, Lambright D & Corvera S. The FYVE domain of early endosome antigen 1 is required for both phosphatidylinositol 3-phosphate and Rab5 binding—critical role of this dual interaction for endosomal localization. J Biol Chem 2000; 275: 3699–705.
